Intellia Therapeutics, Inc. (NTLA) Stock Profile — Insider Trades & Financials

Revenue$23.0M

Net Income-$95.8M

EPS$-3.81

Market Cap$1.6B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

John Leonard

CEO & Executive Director

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

Founded: 2014
Employees: 598
Headquarters: CAMBRIDGE, MA, United States
Website

⚡

Core Efficiency

ROE?

-14.27%

ROA?

-11.37%

D/E Ratio?

0.25

Op. Margin?

-428.86%

📊

Profitability Ratios

Net Margin?

-416.15%

Loading company sections...

Intellia Therapeutics, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness